Press Releases for UTHR

Press Releases
Licensing Executives Society Announces 2009 Deals of Distinction Awards
United Therapeutics Corporation Reports Second Quarter 2009 Financial Results
FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
United Therapeutics Corporation (UTHR) Chairman and Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
United Therapeutics Reports First Quarter 2009 Financial Results
Richard Giltner Joins United Therapeutics Board of Directors
U.S. Food and Drug Administration Extends Action Date for Inhaled Treprostinil (Tyvaso) New Drug Application by Three Months
United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
MaybachFinancial.Com Posts Free Analyst Report on SONC, UTHR, SNDA and PSUN
United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
Critics Say Stock Option Exchanges Unfair
United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results
United Therapeutics to Announce 2008 Fourth Quarter and Annual Financial Results Before Market Open on Tuesday, February 17, 2009
Semi-Annual Changes to the NASDAQ Q-50 Index - Dec 12 2008 8:41PM
Zacks Analyst Blog Highlights: Huntington Bancshares Inc., United Therapeutics Corp., Eli Lilly & Co., Siemens AG and PMI Group Inc.
Zacks Analyst Blog Highlights: United Therapeutics Corp., Eli Lilly & Co., Pfizer Inc., Cost Plus, Inc. And Ultra Clean Holdings, Inc.
Zacks Analyst Blog Highlights: United Therapeutics Corp., Eli Lilly &Co., Pfizer Inc., Cost Plus, Inc. And Ultra Clean Holdings, Inc.
Lilly Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics
FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint
United Therapeutics Reports Third Quarter 2008 Financial Results
United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
Standard & Poor's Announces Changes to U.S. Indices - 09-09-08
Inhaled Treprostinil New Drug Application Filed by FDA
United Therapeutics Reports Second Quarter 2008 Financial Results
United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration
Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration - May 27 2008 1:01AM
Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society - Jun 2 2008 1:48AM
United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders - Jun 2 2008 1:48AM
United Therapeutics Reports First Quarter 2008 Financial Results - Jun 2 2008 1:48AM
United Therapeutics to Announce First Quarter 2008 Financial Results Before Market Open on Thursday, May 1, 2008